Tuesday, January 04, 2011
Save $30 on PEPID which will continue to support Palm Devices (webOS)
Use the promo code SWITCH1.
Here are also a few snippets from a recent PEPID press release:
PEPID® Will Continue to Support Palm Devices
Phoenix, AZ — January 4, 2011 — PEPID, the leading developer of clinical decision-support information and technology for doctors and nurses, announced today they will continue add new features and support all Palm devices.
“We are committed to making PEPID available for every device and operating system on the market,” says John Wagner, president. “Healthcare professionals can choose any device they prefer and be confident that PEPID will always be available.”
As the original developer of point-of-care medical applications for the Web OS operating system and the original Palm devices, PEPID has many exciting updates planned for 2011 for the application, including performance enhancements and new features.
“Our company’s history began with Palm devices in the 90s and we will continue to develop for Palm in the future,” says Wagner. “PEPID has always been the first to develop applications for Palm, and we aren’t going anywhere.”
PEPID has provided clinical specialty-focused products since 1994 when its original application was released for Palm, focusing on the way healthcare professionals practice medicine. PEPID offers one of the most robust medical information resources on the market as well as some of the best customer service in the industry.
PEPID contains the most extensive drug database on the market today, along with thousands of disease profiles and medical conditions, medical and dosing calculators, a drug interactions checker, illustrations, laboratory values and a differential diagnosis generator. All PEPID’s clinical decision support data and tools can be access on any mobile devices, including iPhone, Android, Windows Mobile, BlackBerry and Palm, or integrated into any healthcare information system, EMR, EHR or EDIS to help meet requirements for meaningful use.
Posted by Unknown at 11:44 AM
Subscribe to: Post Comments (Atom)
Post a Comment